Miraculins begins gastric cancer validation s
Miraculins begins gastric cancer validation study
2006-11-06 09:41 ET - News Release
Dr. Jim Charlton reports
MIRACULINS COMMENCES GASTRIC CANCER VALIDATION STUDY
Miraculins Inc. has begun the validation study for its gastric cancer biomarkers.
Miraculins announced the initiation of its gastric cancer (stomach cancer) diagnostic research program in September, 2006. This validation study represents the next step in confirming the diagnostic relevance of the numerous markers detected during an earlier discovery phase study.
"A simple blood based test for diagnosis of gastric cancer does not exist, and that is why we are so excited about these promising biomarkers" said Dr. Jim Charlton, president of Miraculins. "The main reason we acquired these markers was because the discovery phase data was so outstanding. Our validation study is an important research milestone on the road to making a significant contribution to early detection of this disease."
Last year in the United States alone, there were over 22,000 new cases of gastric cancer reported, and over 11,000 deaths. The initial diagnosis of gastric cancer is often delayed because up to 80 per cent of patients do not show symptoms during the early stages of the disease. Most cases of gastric cancer are discovered only after the disease has advanced. Current diagnostic methods for gastric cancer are predominantly image based, invasive and expensive, resulting in low compliance in the general population. The diagnosis of gastric cancer could be dramatically improved with the availability of reliable biomarker based tests.
"We have already collected all of the samples required for this study and they are being prepared for analysis utilizing our BEST platform," added Dr. Charlton. "We are careful when we do our discovery and validation research, to collect enough samples as to ensure that the results have statistical relevance."
We seek Safe Harbor.